Tonix Pharma (TNXP) has released an update to notify the public and investors about a regulation fd disclosure.
Tonix Pharmaceuticals Holding Corp. announced on January 31, 2024, that their research found individuals with chronic overlapping pain conditions (COPCs) are at a higher risk of developing Long COVID symptoms. The press release detailing these findings is filed but is not considered “filed” under specific sections of the United States Securities Exchange Act, nor is it included in filings unless explicitly referenced.
For further insights into TNXP stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
